In the latest trading session, 1.23 million Novo Nordisk ADR (NYSE:NVO) shares changed hands as the company’s beta touched 0.42. With the company’s most recent per share price at $116.42 changed hands at -$0.91 or -0.78% at last look, the market valuation stands at $388.66B. NVO’s current price is a discount, trading about -27.25% off its 52-week high of $148.15. The share price had its 52-week low at $92.94, which suggests the last value was 20.17% up since then. When we look at Novo Nordisk ADR’s average trading volume, we note the 10-day average is 3.33 million shares, with the 3-month average coming to 3.93 million.

Analysts gave the Novo Nordisk ADR (NVO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.94. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NVO as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Novo Nordisk ADR’s EPS for the current quarter is expected to be 0.88.

Novo Nordisk ADR (NYSE:NVO) trade information

Instantly NVO was in red as seen in intraday trades today. With action -1.18%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 12.54%, with the 5-day performance at -1.18% in the red. However, in the 30-day time frame, Novo Nordisk ADR (NYSE:NVO) is -5.89% down. Looking at the short shares, we see there were 7.03 million shares sold at short interest cover period of 1.82 days.

The consensus price target for the stock as assigned by Wall Street analysts is 158, meaning bulls need an upside of 26.32% from its recent market value. According to analyst projections, NVO’s forecast low is 156 with 160 as the target high. To hit the forecast high, the stock’s price needs a -37.43% plunge from its current level, while the stock would need to soar -34.0% for it to hit the projected low.

Novo Nordisk ADR (NVO) estimates and forecasts

Data shows that the Novo Nordisk ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -9.50% over the past 6 months, a 13.70% in annual growth rate that is considerably higher than the industry average of 6.20%. Year-over-year growth is forecast to reach 26.50% up from the last financial year.

Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 10.48B. 4 analysts are of the opinion that Novo Nordisk ADR’s revenue for the current quarter will be 11.49B. The company’s revenue for the corresponding quarters a year ago was 8.55B and 9.4B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 22.60%. The estimates for the next quarter sales put growth at 22.30%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 16.48%. The 2024 estimates are for Novo Nordisk ADR earnings to increase by 23.72%, but the outlook for the next 5-year period is at 18.21% per year.

NVO Dividends

Novo Nordisk ADR is expected to release its next quarterly earnings report on 2024-Nov-06. The 1.24% annual yield figure for the share gives it an annual dividend of 1.45. It is important to note, however, that the 1.24% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 1.48 per year.

Novo Nordisk ADR (NYSE:NVO)’s Major holders

FMR LLC holds the second largest percentage of outstanding shares, with 0.4371% or 19.49 million shares worth $2.78 billion as of 2024-06-30.